Safety (grade 3–4 adverse events) of regimens used as front-line treatment in elderly patients with multiple myeloma.
| Regimen . | N . | Neutropenia, % . | Thrombo- cytopenia, % . | Infection, % . | Peripheral neuropathy, % . | VTE, % . | Study . |
|---|---|---|---|---|---|---|---|
| *Grade 2–4. | |||||||
| †Updated information was presented at the meeting (American Society of Clinical Oncology, European Haematology Association and American Society of Hematology congress). | |||||||
| N indicates number of patients; MPT, melphalan-prednisone-thalidomide; VMP, bortezomib-melphalan-prednisone; VTP, bortezomib-thalidomide-prednisone: VMPT, bortezomib-melphalan-prednisone-thalidomide; CTD, cyclophosphamide-thalidomide-dexamethasone; MPR, melphalan-prednisone-lenalidomide; ND, not determined. | |||||||
| MPT | 129 | 16 | 3 | 10 | 8 | 9 | Palumbo et al19,20 |
| MPT | 125 | 48 | 14 | 13 | 6 | 12 | Facon et al21 |
| MPT | 113 | 23* | ND | ND | 20* | 6 | Hulin et al22 |
| MPT | 165 | ND | ND | 14 | 9 | 3 | Wijermans et al23 † |
| VMP | 344 | 40 | 38 | 11 | 13 | 1 | S Miguel et al25,26 † |
| VMP | 177 | 28 | 17 | 9 | 2 | 2 | Palumbo et al28 † |
| VMP | 130 | 37 | 22 | 7 | 5 | <1 | Mateos et al27 † |
| VTP | 130 | 21 | 12 | <1 | 9 | 4 | Mateos et al27 † |
| VMPT | 152 | 32 | 21 | 13 | 6 | 3 | Palumbo et al28 † |
| CTD | 450 | ND | ND | ND | ND | ND | Morgan et al29 |
| MPR | 54 | 52 | 23 | 10 | 0 | 5 | Palumbo et al30,31 † |
| Regimen . | N . | Neutropenia, % . | Thrombo- cytopenia, % . | Infection, % . | Peripheral neuropathy, % . | VTE, % . | Study . |
|---|---|---|---|---|---|---|---|
| *Grade 2–4. | |||||||
| †Updated information was presented at the meeting (American Society of Clinical Oncology, European Haematology Association and American Society of Hematology congress). | |||||||
| N indicates number of patients; MPT, melphalan-prednisone-thalidomide; VMP, bortezomib-melphalan-prednisone; VTP, bortezomib-thalidomide-prednisone: VMPT, bortezomib-melphalan-prednisone-thalidomide; CTD, cyclophosphamide-thalidomide-dexamethasone; MPR, melphalan-prednisone-lenalidomide; ND, not determined. | |||||||
| MPT | 129 | 16 | 3 | 10 | 8 | 9 | Palumbo et al19,20 |
| MPT | 125 | 48 | 14 | 13 | 6 | 12 | Facon et al21 |
| MPT | 113 | 23* | ND | ND | 20* | 6 | Hulin et al22 |
| MPT | 165 | ND | ND | 14 | 9 | 3 | Wijermans et al23 † |
| VMP | 344 | 40 | 38 | 11 | 13 | 1 | S Miguel et al25,26 † |
| VMP | 177 | 28 | 17 | 9 | 2 | 2 | Palumbo et al28 † |
| VMP | 130 | 37 | 22 | 7 | 5 | <1 | Mateos et al27 † |
| VTP | 130 | 21 | 12 | <1 | 9 | 4 | Mateos et al27 † |
| VMPT | 152 | 32 | 21 | 13 | 6 | 3 | Palumbo et al28 † |
| CTD | 450 | ND | ND | ND | ND | ND | Morgan et al29 |
| MPR | 54 | 52 | 23 | 10 | 0 | 5 | Palumbo et al30,31 † |